-
公开(公告)号：US20240295545A1
公开(公告)日：2024-09-05
申请号：US18276956
申请日：2022-02-11
Applicant: Imperial College Innovations Limited
Inventor： Valentin K. Gribkoff , Kambiz N. Alavian , Travis S. Tierney
IPC: G01N33/50 , A61K31/075 , A61K31/381 , A61K31/423 , A61K31/426 , A61K31/44 , A61K31/495 , A61P35/00 , G01N21/64
CPC classification number: G01N33/5079 , A61K31/075 , A61K31/381 , A61K31/423 , A61K31/426 , A61K31/44 , A61K31/495 , A61P35/00 , G01N21/6428 , G01N33/5058 , G01N2500/10
Abstract: The invention is directed to a method for identifying a candidate anti-glioma drug that is a mitochondrial F1Fo ATP Synthase c-subunit leak channel opener, the method comprising: a. providing an admixture comprising: i. a candidate drug; ii. a submitochondrial vesicle (SMV) preparation; and iii. an H+ probe, wherein the H+ probe remains outside of the SMV(s); b. contacting the admixture with ATP; c. measuring a level of H+ outside of the SMV(s) via the H+ probe; d. comparing the level of H+ at step c) with a level of H+ in a control admixture lacking the candidate drug; and identifying the drug as a candidate anti-glioma drug that is a mitochondrial F1Fo ATP Synthase c-subunit leak channel opener, when the level of H+ is higher compared to the level of H+ in the control admixture; or identifying that the drug is not a candidate anti-glioma drug that is a mitochondrial F1Fo ATP Synthase c-subunit leak channel opener, when the level of H+ is the same or lower compared to the level of H+ in the control admixture.
-
2.发明申请公开(公告)号：US20220249395A1
公开(公告)日：2022-08-11
申请号：US17727301
申请日：2022-04-22
Applicant: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE
Inventor： Kuo-Kuei HUANG , I-Hong PAN , Shu-Fang WEN , Meng-Nan LIN , I-Huang LU , Zong-Keng KUO , Chu-Hsun LU , Tze-Chung LEE , Ya-Yan YANG , Jia-Horng LIAW , Pei-Hsin LIN
IPC: A61K31/047 , A61K31/215 , A61K31/335 , A61K9/50 , A61K31/352 , A61K9/00 , A61K31/045 , A61P37/00 , A61P25/28 , A61K9/08 , A61K9/14 , A61K31/075 , A61K31/122 , A61K31/222 , A61K31/343 , A61K47/02 , A61K47/26 , A61K47/34 , A61K47/38 , A61K47/40
Abstract: A method for treating an autoimmune neurological disease and/or a neurodegenerative disease is provided. The method includes administering an effective amount of at least one compound having Formula (I), Formula (II) or Formula (III), or its geometric isomer, enantiomer or diastereomer to a subject in need thereof: wherein is a single or double bond, X is NCH3 or CH2, Y is null, O or N, Z is O or N, R1 is H, OH, and R2 is null, H, C1-C8 alkyl, —(C═O)-alkyl, —(C═O)-aryl, —(C═O)-alkyl-aryl, —(C═O)-heteroaryl, cycloalkyl or heterocycloalkyl, which optionally substituted by one or more of —OH, —NO2, —NH2, —NR3R4, carbonyl, alkoxyl, alkyl or —OCF3, wherein R3 and R4 independently are H, alkyl, O2CH3, —(C═O)—CH3 or (C═O)—NH2.
-
公开(公告)号：US10933009B2
公开(公告)日：2021-03-02
申请号：US15979056
申请日：2018-05-14
Applicant: VAPOGENIX, INC.
Inventor： Danguole Spakevicius
Abstract: The present invention provides compositions and methods for treating a dermatological disorder or disease.
-
公开(公告)号：US20190290639A1
公开(公告)日：2019-09-26
申请号：US16438956
申请日：2019-06-12
Applicant: 442 Ventures, LLC
Inventor： J. Mark JACKSON
IPC: A61K31/4745 , A61K31/4436 , A61K9/00 , A61K45/06 , A61K31/60 , A61K31/437 , A61K31/203 , A61K31/075 , A61K31/07
Abstract: Compositions and methods for treatment of conditions affecting skin and/or mucosal surfaces of a subject that make use of an imidazoquinoline compound and a retinoid agent are described.
-
公开(公告)号：US10406164B2
公开(公告)日：2019-09-10
申请号：US15902491
申请日：2018-02-22
Applicant: The General Hospital Corporation
Inventor： David R. Elmaleh
IPC: A61K31/13 , A61K31/55 , A61K38/18 , A61K39/00 , A61K45/06 , A61K48/00 , A61K51/04 , C07K16/18 , A61K31/047 , A61K31/075 , A61K31/192 , A61K31/194 , A61K31/225 , A61K31/352 , A61K31/353 , A61K31/428 , A61K31/435 , A61K31/438 , A61K31/706 , A61K31/713 , A61K31/5415
Abstract: The present invention relates to combination therapies for treating Alzheimer's disease or an amyloidosis-associated pathological condition comprising co-administering a therapeutically effective amount of a first compound, and a therapeutically effective amount of a second compound. In certain embodiments, the first compound or the second compound inhibits AB peptide polymerization; is an anti-inflammatory; improves cognitive function, mood, or social behavior; is associated with Tau or alpha-synuclein; or regulates amyloid peptide washout.
-
Patent Agency Ranking
公开(公告)号：US10398704B2
公开(公告)日：2019-09-03
申请号：US15902498
申请日：2018-02-22
Applicant: The General Hospital Corporation
Inventor： David R. Elmaleh
IPC: A61K31/5415 , A61K45/06 , A61K31/192 , A61K31/352 , A61K31/428 , A61K31/438 , A61K31/706 , A61K31/047 , A61K31/225 , A61K31/435 , A61K51/04 , A61K31/13 , A61K31/194 , A61K31/075 , A61K31/55 , A61K31/713 , A61K38/18 , A61K39/00 , C07K16/18 , A61K31/353 , A61K48/00
Abstract: The present invention relates to combination therapies for treating Alzheimer's disease or an amyloidosis-associated pathological condition comprising co-administering a therapeutically effective amount of a first compound, and a therapeutically effective amount of a second compound. In certain embodiments, the first compound or the second compound inhibits AB peptide polymerization; is an anti-inflammatory; improves cognitive function, mood, or social behavior; is associated with Tau or alpha-synuclein; or regulates amyloid peptide washout.
-
公开(公告)号：US10307383B2
公开(公告)日：2019-06-04
申请号：US15945601
申请日：2018-04-04
Inventor： Ha Won Kim , Dong Hee Lee
IPC: A61K31/045 , A61K31/015 , A61P17/06 , A61P17/04 , A61P37/00 , A61K31/075 , A61K31/12 , A61K31/215 , A61K31/336
Abstract: The present invention relates to a pharmaceutical composition for preventing or treating autoimmune diseases having cedrol or a pharmaceutically acceptable salt thereof as an active ingredient. Particularly, the cedrol or the derivative thereof of the present invention inhibits the expression of IL-17A, and in particular, cedrol, cedryl acetate, and cedrene exhibit the effect of delaying the outbreak of psoriasis and treating thereof in a psoriasis animal model. Therefore, these compounds can be used for the treatment of autoimmune diseases mediated by IL-17.
-
公开(公告)号：US20190125776A1
公开(公告)日：2019-05-02
申请号：US16171862
申请日：2018-10-26
Applicant: Dow Pharmaceutical Sciences, Inc.
Inventor： Yunik Chang , Gordon J. Dow , Radhakrishnan Pillai
IPC: A61K31/7056 , A61K31/327 , A61K47/32 , A61K9/00 , A61K47/10 , A61K8/38 , A61K45/06 , A61Q19/00 , A61K9/14 , A61K31/235 , A61K31/075 , A61K8/34 , A61K8/55 , A61K8/04 , A61K8/02
Abstract: An aqueous formulation for topical application to the skin comprising water, a water-miscible organic solvent, and benzoyl peroxide, wherein the concentration of the organic solvent is sufficient to provide a stable suspension of benzoyl peroxide in the aqueous formulation without the inclusion of a surfactant in the formulation, wherein the ratio of concentrations of water and organic solvent in the formulation is sufficient to maintain the benzoyl peroxide in saturated solubility in the formulation following application to the skin, and wherein the concentration of benzoyl peroxide in the formulation is less than 5.0% and at least 1.0% w/w. The formulation may further contain a chemical compound in addition to benzoyl peroxide that is effective in the treatment of acne. The aqueous formulations of the invention are useful in the treatment of acne and acne rosacea.
-
公开(公告)号：US10145855B2
公开(公告)日：2018-12-04
申请号：US15585773
申请日：2017-05-03
Applicant: Synapse Biosciences, LLC
Inventor： Robert Anthony Millet, Jr. , Philip T. Radford , Ashwin Anand Patkar
IPC: G01N33/94 , G01N33/493 , C07D307/00 , C07D277/00 , A61K31/075 , A61K31/10 , A61K31/13 , A61B5/00
Abstract: Provided herein are methods and dose packs for the monitoring of medication adherence. In one aspect, the dose pack comprises comprise a multiplicity of doses of an agent and a multiplicity of doses of a marker and be configured to isolate a pair of at least one of the multiplicity of doses of the agent and at least one of the multiplicity of doses of the marker for co-administration of the pair to the subject according to the dosing schedule. In another aspect, the method comprises obtaining a sample from the subject subsequent to the conclusion of a monitoring window and analyzing the sample for the presence or absence of a marker or a degradation product thereof.
-
公开(公告)号：US20180256477A1
公开(公告)日：2018-09-13
申请号：US15979056
申请日：2018-05-14
Applicant: VAPOGENIX, INC.
Inventor： DANGUOLE SPAKEVICIUS
Abstract: The present invention provides compositions and methods for treating a dermatological disorder or disease.
-
-
-
-
-
-
-
-
-
Search Results
774
records
(took 0.028 seconds)
